Tous Actualités
Suivre
Abonner Intercell AG

Intercell AG

Intercell and the PATH Malaria Vaccine Initiative Announce New Collaboration for a Vaccine against Malaria

Wien (euro adhoc) -

» Malaria vaccine candidates selected by the PATH Malaria Vaccine  
  Initiative will be formulated with ICLL’s adjuvant IC31®
» The project, funded by PATH, will evaluate the potency of  
  Intercell´s novel adjuvant IC31® in the field of malaria
  ots.CorporateNews transmitted by euro adhoc. The issuer is responsible for
  the content of this announcement.
research
Vienna (Austria), Seattle (USA), January 16, 2008
- Intercell AG (VSE, "ICLL") and the PATH Malaria Vaccine Initiative 
announce a new collaboration to evaluate Intercell's novel 
proprietary adjuvant IC31® in combination with recombinant malaria 
antigens from the National Institutes of Health (NIH). The work will 
be performed at Intercell and funded by PATH. The aim of these 
studies is to demonstrate whether or not IC31®, in combination with 
NIH's antigens, triggers an immune response when evaluated in 
animals. First results of the studies are expected by the end of 
2008.
"The development of a malaria vaccine is a great challenge and needs 
the combination of the best vaccine components available today," 
explains Intercell´s Chief Scientific Officer Alexander von Gabain. 
"The diversity, complexity, and different life stages of the malaria 
parasite require an optimal choice of antigens and adjuvants in order
to deliver a protective vaccine. Our partner provides not only 
excellent and validated antigens, but also a long-standing track 
record in the malaria arena. Thus, we believe that it´s a great step 
forward to develop a malaria vaccine containing our proprietary 
adjuvant IC31® which has shown to facilitate the induction of 
specific antibodies, but also a strong T-cell response, a feature 
needed to protect against an intracellular pathogen, such as 
plasmodia. We are looking forward to a fruitful and successful 
partnership!"
"The PATH Malaria Vaccine Initiative is very excited about the 
possibilities that this opportunity presents for the field, as 
adjuvants have been identified as a critical gap in the development 
of a malaria vaccine by donors and international agencies," said 
Christian Loucq, MD, director of the PATH Malaria Vaccine Initiative.
"Any time that we are able to find and evaluate novel adjuvants that 
can be applied to malaria vaccine development, we take another step 
toward our goal of developing a safe and effective vaccine for 
children in Africa and toward the long-term goal of eradicating 
malaria."
About Malaria
Malaria is one of the most common infectious diseases and an enormous
public health problem. Malaria causes about 400-900 million cases of 
fever and approximately one to three million deaths annually — this 
represents at least one death every 30 seconds. Malaria is 
transmitted to humans through the bites of infected female Anopheles 
mosquitoes. The resulting disease in humans can be devastating. After
spreading rapidly through the bloodstream to the liver, the parasite 
emerges again into the blood stream, to settle finally in the red 
blood cells, where it multiplies and emerges in bursts of new 
organisms. These parasites, because of their large numbers, can cause
particular damage to the nervous system, liver, and kidney.
In young children and adults who have not recently been infected (and
therefore have not developed natural immunity), this cycle can result
in death within hours from cerebral malaria. Others die later in the 
infection from overwhelming anemia or liver and kidney failure. 
Untreated, up to 20% of persons infected with malaria will die.
Malaria is not just a disease commonly associated with poverty, but 
is also a cause of poverty and a major hindrance to economic 
development. The disease has been associated with major negative 
economic effects on regions where it is widespread. In its entirety, 
the economic impact of malaria has been estimated to cost Africa $12 
billion USD every year. The economic impact includes costs of health 
care, working days lost due to sickness, days lost in education, 
decreased productivity due to brain damage from cerebral malaria, and
loss of investment and tourism. In some countries with a heavy 
malaria burden, the disease may account for as much as 40% of public 
health expenditure, 30-50% of inpatient admissions, and up to 50% of 
outpatient visits.
About IC31®
Adjuvants enhance the effectiveness of vaccines. Existing adjuvants 
on the market induce antibodies but no or little T-cell immunity. 
IC31® is an adjuvant inducing both T-cell and B-cell responses with a
unique synthetic formulation which combines the immunostimulating 
properties of an anti-microbial peptide, KLK, and an 
immunostimulatory oligodeoxynucleotide, ODN1a. The two-component 
solution can be simply mixed with antigens, no conjugation is 
required. Intercell currently has IC31® collaborations with a number 
of global vaccine companies, as well as small biotechs. IC31® has 
also been partnered with Novartis and Wyeth for the development of 
several new vaccines against infectious diseases.
About the PATH Malaria Vaccine Initiative
The PATH Malaria Vaccine Initiative (MVI) is a global program 
established in 1999 with a grant from the Bill & Melinda Gates 
Foundation. The PATH Malaria Vaccine Initiative´s mission is to 
accelerate the development of promising vaccines and ensure their 
availability and accessibility in the developing world. For more 
information, visit www.malariavaccine.org.
PATH is an international, nonprofit organization that creates 
sustainable, culturally relevant solutions, enabling communities 
worldwide to break longstanding cycles of poor health. By 
collaborating with diverse public- and private-sector partners, PATH 
helps provide appropriate health technologies and vital strategies 
that change the way people think and act. PATH´s work improves global
health and well-being.
For more information, visit www.path.org.
end of announcement                               euro adhoc

Further inquiry note:

Intercell AG
Lucia Malfent
Head of Corporate Communications
Campus Vienna Biocenter 2
A-1030 Vienna
P: +43-1-20620-303
Mail to: LMalfent@intercell.com

The PATH Malaria Vaccine Initiative
Preeti Singh
Burness Communications
7910 Woodmont Avenue, Ste. 700 Bethesda, MD 20814-7034
P: +1 301-652-1558
Mail to: Psingh@burnesscommunications.com

Branche: Biotechnology
ISIN: AT0000612601
WKN: A0D8HW
Börsen: Wiener Börse AG / official market

Plus de actualités: Intercell AG
Plus de actualités: Intercell AG